Therapeutic Response

IDH1 p.R132C status confers therapeutic sensitivity to Olutasidenib in patients with Acute Myeloid Leukemia.

Statements

Source and description
Rezlidhia (olutasidenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.